OBJECTIVE: Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. Herein, we describe the clinical features and outcomes for a large series of ACC patients. DESIGN AND METHODS: Retrospective review of ACC patients seen at The University of Texas MD Anderson Cancer Center from 1998 through 2011. RESULTS: A total of 330 patients with median age at diagnosis of 48.5 years; 12 (3.6%) patients were under 18 years. Hormonally functioning tumors represented 41.8% (n=138) of all cases. Surgical resection for the primary tumor was done in 275 (83.3%) patients (45 at MD Anderson (16.4%)). For those who had surgical resection, the median local-recurrence-free time was 1.04 years. Factors associated with local recurrence included positive surgical margins (P=0.007) and advanced disease stage (P=0.026). Median overall survival time for all patients was 3.21 years. Median survival times were 24.1, 6.08, 3.47, and 0.89 years for stages I, II, III, and IV respectively. In multivariable analysis, older age, functioning tumors, and higher disease stage remained significant prognostic factors associated with poor survival. CONCLUSION: ACC prognosis remains poor with the use of currently available treatments. Older age, functioning tumors, and incomplete resections are clinical factors associated with poor survival. Surgical expertise is important to achieve complete resections and to improve outcome.
OBJECTIVE:Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. Herein, we describe the clinical features and outcomes for a large series of ACC patients. DESIGN AND METHODS: Retrospective review of ACC patients seen at The University of Texas MD Anderson Cancer Center from 1998 through 2011. RESULTS: A total of 330 patients with median age at diagnosis of 48.5 years; 12 (3.6%) patients were under 18 years. Hormonally functioning tumors represented 41.8% (n=138) of all cases. Surgical resection for the primary tumor was done in 275 (83.3%) patients (45 at MD Anderson (16.4%)). For those who had surgical resection, the median local-recurrence-free time was 1.04 years. Factors associated with local recurrence included positive surgical margins (P=0.007) and advanced disease stage (P=0.026). Median overall survival time for all patients was 3.21 years. Median survival times were 24.1, 6.08, 3.47, and 0.89 years for stages I, II, III, and IV respectively. In multivariable analysis, older age, functioning tumors, and higher disease stage remained significant prognostic factors associated with poor survival. CONCLUSION: ACC prognosis remains poor with the use of currently available treatments. Older age, functioning tumors, and incomplete resections are clinical factors associated with poor survival. Surgical expertise is important to achieve complete resections and to improve outcome.
Authors: M Terzolo; A Boccuzzi; S Bovio; S Cappia; P De Giuli; A Alì; P Paccotti; F Porpiglia; D Fontana; A Angeli Journal: Urology Date: 2001-01 Impact factor: 2.649
Authors: Ilse G C Hermsen; Thomas M A Kerkhofs; Gijsbert den Butter; Job Kievit; Casper H J van Eijck; Els J M Nieveen van Dijkum; Harm R Haak Journal: Surgery Date: 2012-07 Impact factor: 3.982
Authors: J M Varley; G McGown; M Thorncroft; L A James; G P Margison; G Forster; D G Evans; M Harris; A M Kelsey; J M Birch Journal: Am J Hum Genet Date: 1999-10 Impact factor: 11.025
Authors: Ilknur Erdogan; Timo Deutschbein; Christian Jurowich; Matthias Kroiss; Christina Ronchi; Marcus Quinkler; Jens Waldmann; Holger S Willenberg; Felix Beuschlein; Christian Fottner; Silke Klose; Anke Heidemeier; David Brix; Wiebke Fenske; Stefanie Hahner; Joachim Reibetanz; Bruno Allolio; Martin Fassnacht Journal: J Clin Endocrinol Metab Date: 2012-11-12 Impact factor: 5.958
Authors: Amanda B Cooper; Mouhammed Amir Habra; Elizabeth G Grubbs; Brian K Bednarski; Anita K Ying; Nancy D Perrier; Jeffrey E Lee; Thomas A Aloia Journal: Surg Endosc Date: 2013-06-14 Impact factor: 4.584
Authors: Thomas M A Kerkhofs; Rob H A Verhoeven; Jan Maarten Van der Zwan; Jeanne Dieleman; Michiel N Kerstens; Thera P Links; Lonneke V Van de Poll-Franse; Harm R Haak Journal: Eur J Cancer Date: 2013-04-03 Impact factor: 9.162
Authors: A Naing; P Lorusso; S Fu; D Hong; H X Chen; L A Doyle; A T Phan; M A Habra; R Kurzrock Journal: Br J Cancer Date: 2013-02-14 Impact factor: 7.640
Authors: Caroline E Poorman; Lauren M Postlewait; Cecilia G Ethun; Thuy B Tran; Jason D Prescott; Timothy M Pawlik; Tracy S Wang; Jason Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Charles A Staley; George A Poultsides; Shishir K Maithel Journal: Am Surg Date: 2017-07-01 Impact factor: 0.688
Authors: Neda Amini; Georgios Antonios Margonis; Yuhree Kim; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Douglas B Evans; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2015-08-18 Impact factor: 5.344
Authors: Georgios Antonios Margonis; Yuhree Kim; Jason D Prescott; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Douglas B Evans; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2015-08-19 Impact factor: 5.344
Authors: Satoshi Takeuchi; Aparna Balachandran; Mouhammed Amir Habra; Alexandria T Phan; Roland L Bassett; Homer A Macapinlac; Hubert H Chuang Journal: Eur J Nucl Med Mol Imaging Date: 2014-07-03 Impact factor: 9.236